ZIKV E Specific Neutra™ Antibody (V3S-0923-XY60), Human IgG (CAT#: V3S-0923-XY60)

Send Inquiry
  • fig1

Datasheet

MSDS

COA

Summary
Property
Applications
Protocols
Target

Summary

Description ZIKV-195 is a potently human neutralizing antibody, which specifically recognizes ZIKV E protein. The potent neutralizing antibody ZIKV-195 broadly inhibits ZIKV strains and has therapeutic potential against ZIKV infection. This product has been detected by Enzyme-linked immunosorbent assay, Flow cytometry and Neutralization assay.
Clonality Monoclonal
Host Species Human
Target Species ZIKV
Cross Reactivity African (Dakar 41525 and MR 766), Asian (H/PF/2013 and Malaysia P6740), American (Paraiba 2015)
Epitope ZIKV-195 binds to both E protomers forming dimers within one icosahedral asymmetric unit.
Neutralization Mechanism ZIKV-195 binds to both E protomers forming dimers, thereby stabilizing the E dimers on the mature ZIKV particle and possibly preventing formation of fusogenic trimers.
IC50 77-600 ng/mL
Isotype Human IgG

Property

Expression Species HEK293F or CHO cell line
Conjugation Unconjugated
Purity >95%
Endotoxin <1 EU/mg
Form Liquid
Purification Protein A purified
Sterility 0.2 μM filtered
Formulation PBS, pH 7.4
Preservation No preservatives
Stabilizer No stabilizers
Storage Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics.

Applications

Application ELISA; FC; Neut
Application Notes Neutralization assay (Neut): Serial dilutions of mAbs were incubated with ∼100 FFU of different ZIKV strains for 1 h at 37°C.

Protocols

ELISA Enzyme-Linked Immunosorbent Assay Protocol
WB Western Blot Protocol
FC Flow Cytometry Protocol

Target

Target ZIKV E
Alternative Name Zika virus envelope protein
Research Area Infectious Disease
Related Disease Severe neurological diseases
For research use only, not directly for clinical use.
banner banner
© 2024 Creative Biolabs. All Rights Reserved.
antibody
Online Inquiry